BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14569059)

  • 1. Oral treatment with recombinant human interleukin-11 improves mucosal transport in the colon of human leukocyte antigen-B27 transgenic rats.
    Venkova K; Keith JC; Greenwood-Van Meerveld B
    J Pharmacol Exp Ther; 2004 Jan; 308(1):206-13. PubMed ID: 14569059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human interleukin-11 restores smooth muscle function in the jejunum and colon of human leukocyte antigen-B27 rats with intestinal inflammation.
    Greenwood-Van Meerveld B; Venkova K; Keith JC
    J Pharmacol Exp Ther; 2001 Oct; 299(1):58-66. PubMed ID: 11561063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease.
    Peterson RL; Wang L; Albert L; Keith JC; Dorner AJ
    Lab Invest; 1998 Dec; 78(12):1503-12. PubMed ID: 9881950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human interleukin-11 modulates ion transport and mucosal inflammation in the small intestine and colon.
    Greenwood-Van Meerveld B; Tyler K; Keith JC
    Lab Invest; 2000 Aug; 80(8):1269-80. PubMed ID: 10950118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology.
    Keith JC; Albert L; Sonis ST; Pfeiffer CJ; Schaub RG
    Stem Cells; 1994; 12 Suppl 1():79-89; discussion 89-90. PubMed ID: 7696971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.
    Bertrand V; Quéré S; Guimbaud R; Sogni P; Chauvelot-Moachon L; Tulliez M; Lamarque D; Charreire J; Giroud JP; Couturier D; Chaussade S; Breban M
    Eur Cytokine Netw; 1998 Jun; 9(2):161-70. PubMed ID: 9681392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease.
    Peterson RL; Wang L; Albert L; Marchese E; Erickson J; Wong A; Mounts WM; Hayes L; Bouchard P; Keith J; Dorner AJ
    Pharmacogenomics J; 2002; 2(6):383-99. PubMed ID: 12629504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nitric oxide synthase inhibition or sulfasalazine on the spontaneous colitis observed in HLA-B27 transgenic rats.
    Aiko S; Fuseler J; Grisham MB
    J Pharmacol Exp Ther; 1998 Feb; 284(2):722-7. PubMed ID: 9454820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromuscular dysfunction in the jejunum and colon of human leukocyte antigen B27 transgenic rats.
    Venkova K; Dunn ST; Adesina AM; Greenwood-Van Meerveld B
    J Pharmacol Exp Ther; 2000 Apr; 293(1):60-6. PubMed ID: 10734153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model.
    Bowen-Yacyshyn MB; Bennett CF; Nation N; Rayner D; Yacyshyn BR
    J Pharmacol Exp Ther; 2002 Sep; 302(3):908-17. PubMed ID: 12183646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effects of recombinant human interleukin-11 on contractile properties in rabbit 2,4,6-trinitrobenzene sulfonic acid colitis.
    Depoortere I; Thijs T; van Assche G; Keith JC; Peeters TL
    J Pharmacol Exp Ther; 2000 Sep; 294(3):983-90. PubMed ID: 10945850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats.
    Breban M; Fernández-Sueiro JL; Richardson JA; Hadavand RR; Maika SD; Hammer RE; Taurog JD
    J Immunol; 1996 Jan; 156(2):794-803. PubMed ID: 8543835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased tissue protein synthesis during spontaneous inflammatory bowel disease in HLA-B27 rats.
    El Yousfi M; Breuillé D; Papet I; Blum S; André M; Mosoni L; Denis P; Buffière C; Obled C
    Clin Sci (Lond); 2003 Oct; 105(4):437-46. PubMed ID: 12793856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondylarthropathy.
    Hacquard-Bouder C; Falgarone G; Bosquet A; Smaoui F; Monnet D; Ittah M; Breban M
    Arthritis Rheum; 2004 May; 50(5):1624-35. PubMed ID: 15146433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta2 microglobulin transgenic rats.
    Blanchard HS; Dernis-Labous E; Lamarque D; Nhieu JT; Szepes Z; Fléjou JF; Wollman E; Whittle BJ; Breban M
    Eur Cytokine Netw; 2001 Mar; 12(1):111-8. PubMed ID: 11282554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats.
    Schultz M; Munro K; Tannock GW; Melchner I; Göttl C; Schwietz H; Schölmerich J; Rath HC
    Clin Diagn Lab Immunol; 2004 May; 11(3):581-7. PubMed ID: 15138186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated measurement of intestinal permeability as an assessment of colitis severity in HLA-B27 transgenic rats.
    Kerr SW; Wolyniec WW; Filipovic Z; Nodop SG; Braza F; Winquist RJ; Noonan TC
    J Pharmacol Exp Ther; 1999 Nov; 291(2):903-10. PubMed ID: 10525115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression.
    Taurog JD; Maika SD; Simmons WA; Breban M; Hammer RE
    J Immunol; 1993 May; 150(9):4168-78. PubMed ID: 8473755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.
    Alavi K; Schwartz MZ; Palazzo JP; Prasad R
    J Pediatr Surg; 2000 Jun; 35(6):847-51. PubMed ID: 10873024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease.
    Harnish DC; Albert LM; Leathurby Y; Eckert AM; Ciarletta A; Kasaian M; Keith JC
    Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G118-25. PubMed ID: 12958017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.